Editorial: Improved efficacy of biological maintenance therapy in early compared with late crohn's disease: Strike while the iron is hot with Anti-TNF agents

American Journal of Gastroenterology

Volumn 105, Issue 7, 2010, Pages 1583-1585

  Ananthakrishnan, Ashwin N ^a   Binion, David G ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; INTERLEUKIN 12 RECEPTOR; NATALIZUMAB; PLACEBO;

ADULT; BIOLOGICAL THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ALGORITHMS; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MULTICENTER STUDIES AS TOPIC; PLACEBOS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 77954395322     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.98     Document Type: Review

References (16)

1. Bathon JM, Martin RW, Fleischmann RM et al. A comparisonof etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593
2. Genovese MC, Bathon JM, Martin R W et al. Etanercept versus methotrex- ate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-1450
3. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn ′ s dis ease. N Engl J Me d 2007; 357: 239-250
4. Schreiber S, Colombel J-F, Bloomfield R et al. In creased resp o n se an d rem is- sion rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECISE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-1582 (this issue).
5. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-238
6. Kugathasan S, Werlin S L, Martinez A et al. Prolonged duration of response to inf iximab in early but not late pediatric Crohn's disease. Am J Gastroen-terol 2000;95:3189-3194
7. Parsi MA, Achkar J P, Richardson S et al. Predictors of response to inf iximab in patients with Crohn's disease. Gastroenterology 2002;123:707-713
8. Vermeire S, Louis E, Carbonez A et al. Demographic and clinical parameters inf uencing the short-term outcome of anti-tumor necrosis factor (inf iximab) treatment in Crohn ′ s dis eas e. Am J Gastroenterol 2002; 97: 2357-2363
9. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with inf iximab in 614 patients with Crohn ′ s disease: results from a single-centre cohort. Gut 2009;58:492-500.
10. Regueiro M, Schraut W, Baidoo L et al. Infiximab prevents Crohn's disease recurrence after ilea l resection. Gastro enterolog y 2009; 136: 441-450 e1; quiz 716.
11. Spencer DM, Veldman GM, Banerjee S et al. Distinct inf ammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002;122:94-105.
12. Kugathasan S, Saubermann LJ, Smith L et al. Mucosal T-cell immunoregulation varies in early and late infammatory bowel disease. Gut 2007;56:1696-1705
13. Desreumaux P, Brandt E, Gambiez L et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn ′ s disease. Gastroenterolog y 1997;113:118-126
14. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with inf iximab: a randomized trial. Ann Intern Med 2007;146:829-838
15. Gonzaga JE, Ananthakrishnan AN, Issa M et al. Durability of infiximab in Crohn's disease: a single-center experience. Inf amm Bowel Dis 2009; 15: 1837-1843
16. Pohl H, Welch HG. The role of overdiagnosis and reclassifi cation in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer